tbuckley/cabot-search huggingface dataset:
Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use
Authors: Jonathan Webster, Leo Luznik, Hua-Ling Tsai, Philip H. Imus, Amy E. DeZern, Keith W. Pratz, Mark Levis, Ivana Gojo, Margaret M. Showel, Gabrielle T. Prince, Javier Bolanos-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Tania Jain, Ephraim J. Fuchs, Douglas E Gladstone, Christian B. Gocke, Abbas Abbas Ali, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Richard J. Jones, B. Douglas Smith
Journal: Blood (2020)
Assessment of outcomes of calciphylaxis
Authors: Colleen K. Gabel, Emily D. Nguyen, Teja Chakrala, Amy E. Blum, Josie François, Sidharth Chand, Renajd Rrapi, Olesya Baker, Allison S. Dobry, Anna Cristina Garza-Mayers, Lauren N. Ko, Radhika Shah, Jessica St. John, Sagar U. Nigwekar, Daniela Kroshinsky
Journal: Journal of the American Academy of Dermatology (2020)
Machine Learning Adds to Clinical and CAC Assessments in Predicting 10-Year CHD and CVD Deaths
Authors: Rine Nakanishi, Piotr J. Slomka, Richard Rios, Julian Betancur, Michael J. Blaha, Khurram Nasir, Michael D. Miedema, John A. Rumberger, Heidi Gransar, Leslee J. Shaw, Alan Rozanski, Matthew J. Budoff, Daniel S. Berman
Journal: JACC. Cardiovascular imaging (2020)
Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation
Authors: Brian D Friend, Larisa Broglie, Brent Logan, Caitrin Fretham, Gary J. Schiller, Bipin N. Savani, Edward Stadtmauer, Saurabh Chhabra, Marcelo C. Pasquini, Monica Thakar, Mohamed Sorror
Journal: Blood (2020)
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
Authors: Raymond L. Comenzo, Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Vaishali Sanchorawala, Hans C. Lee, Simon D. Gibbs, Peter Mollee, Christopher P. Venner, Jin Lu, Stefan Schönland, Moshe Gatt, Kenshi Suzuki, Kihyun Kim, M. Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania T. M. Hungria, Sandy W. Wong, Michael Rosenzweig, Naresh Bumma, Dominique Chauveau, Meletios A Dimopoulos, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brenda Tromp, Brendan M. Weiss, Jessica Vermeulen, Giampaolo Merlini
Journal: Blood (2020)
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Authors: Antonio Rivero-Juarez, Francisco Tellez, Maria Isabel Mayorga, Dolores Merino, Nuria Espinosa, Juan Macias, Rosario Palacios, María Paniagua, Antonio Collado, Omar Mohamed, Javier Perez-Stachowski, Jose Hernandez-Quero, Elisa Fernandez-Fuertes, Antonio Rivero
Journal: Clinical Microbiology and Infection (2020)
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
Authors: Evangelos Terpos, Marianna Politou, Theodoros N Sergentanis, Andreas Mentis, Vassiliki Pappa, Maria Pagoni, Elisavet Grouzi, Stavroula Labropoulou, Ioanna Charitaki, Dimitra Moschandreou, Anthi Bouhla, Stylianos Saridakis, Eleni Korompoki, Chara Giatra, Tina Bagratuni, Angelos Pefanis, Sotirios Papageorgiou, Alexandros Spyridonidis, Anastasia Antoniadou, Anastasia Kotanidou, Konstantinos Syrigos, Konstantinos Stamoulis, George Panayiotakopoulos, Sotirios Tsiodras, Leonidas Alexopoulos, Meletios A Dimopoulos
Journal: Blood (2020)
Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients &amp;gt; 75 Years Old: A Retrospective Analysis
Authors: Abdullah S. Al Saleh, Alissa Visram, Harsh Parmar, Angela Dispenzieri, Eli Muchtar, Francis K. Buadi, Rahma M Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis Kourelis, Morie A. Gertz, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2020)
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
Authors: Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre H. Goy, Rene-Olivier Casasnovas, Stephen D. Smith, Gandhi Laurent Damaj, Jeanette K. Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P. Kater, Steven Le Gouill, Lucie Oberic, Tadeusz Robak, Preetesh Jain, Graham Brock, Priti Patel, Lin Tao, Monika Dlugosz-Danecka
Journal: Blood (2020)
Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist
Authors: Manisha Balwani, Herbert L. Bonkovsky, Kirstine J Belongie, Karl E Anderson, Fumihiro Takahashi, Antonio Irizarry, Mark Amster, D. Montgomery Bissell, Bruce Wang, Lydie Hazan, Charles J. Parker, Edward Cordasco, Cynthia Levy, Robert J. Desnick
Journal: Blood (2020)
The Effect of Macrophage Polarization on Cytokine Release in CAR-T Antitumor Response
Authors: Ekaterina Zmievskaya, Aigul Valiullina, Margarita Zhuravleva, Aigul R Rakhmatullina, Irina Ganeeva, Ekaterina Zaikova, Alexey Petukhov, Regina R Miftakhova, Albert A Rizvanov, Emil Bulatov
Journal: Blood (2020)
Abstract 10347: Prognostic Value of the Combination of Pulmonary-systemic Pressure Ratio and Model Of End-stage Liver Disease Excluding Inr (meld-xi) Score in Patients Admitted for Acute Decompensated Heart Failure
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Jun Nakamura, Kyoko Yamamoto, Makoto Abe, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Tamura Yuto, Takeshi Fujita, Masatake Fukunami
Journal: Circulation (2019)

Backgrounds: Concomitant presence of pulmonary hypertension in heart failure is associated with increased adverse events and may be related to interventricular uncoupling and impaired cardiac effic...
Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
Authors: Michael Wang, John M. Rossi, Javier Munoz, Andre H. Goy, Frederick L. Locke, Patrick M. Reagan, Caron A. Jacobson, Brian T. Hill, Houston Holmes, Samantha Jaglowski, Weimin Peng, Lianqing Zheng, Xiang Fang, Allen Xue, Ioana Kloos, Adrian Bot
Journal: Blood (2020)
Children Diagnosed with Acute Leukemia of Ambiguous Lineage (ALAL) Benefit from Acute Myeloid Leukemia (AML) Treatment Protocols: A Retrospective Analysis from a Single Center
Authors: Georgia Avgerinou, Ilona Binenbaum, Stavros Glentis, Marianna Tzannoudaki, Stefanos Papadhimitriou, Efthimia Rigatou, Katerina Katsibardi, Natalia Tourkantoni, Haroula Tsipou, Kleoniki Roka, Antonia Vlachou, Maria Filippidou, Antonis Kattamis
Journal: Blood (2020)
Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis
Authors: Christopher J. Forlenza, Nitya Gulati, Audrey Mauguen, Michael J. Absalon, Sharon M. Castellino, Anna Franklin, Frank G. Keller, Neal Shukla
Journal: Blood (2020)
Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
Authors: Simard Camille, Maral Koolian, Diana Escobar, Mark Blostein, Jed Lipes, Adelina Teona Avram, Ryan Kerzner, Helen Mantzanis, Mateo Porres Aguilar, Vicky Tagalakis
Journal: Blood (2020)
Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)
Authors: Franco Locatelli, Michael B. Jordan, Carl Allen, Simone Cesaro, Carmelo Rizzari, Anupama Rao, Barbara Degar, Tim Garrington, Julian Sevilla, Maria Caterina Putti, Franca Fagioli, Martina Ahlmann, Jose-Luis Dapena Diaz, Michael Henry, Fabrizio De Benedetti, Alexei Grom, Anna Stoltenberg, Mårten Vågerö, Cristina de Min
Journal: Blood (2020)
Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Eunice S. Wang, Jessica K. Altman, Kristen Pettit, Stephane De Botton, Roland P Walter, Pierre Fenaux, Francis Burrows, Blake E. Tomkinson, Bridget Martell, Amir T. Fathi
Journal: Blood (2020)
Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older
Authors: Paul J. Hampel, Timothy G. Call, Kari G Rabe, Sara J. Achenbach, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Amber B. Koehler, Jose F. Leis, Susan M. Schwager, Daniel L. Van Dyke, Min Shi, Curtis A. Hanson, Tait Shanafelt, Esteban Braggio, Susan L. Slager, Neil E. Kay, Wei Ding, Sameer A. Parikh
Journal: Blood (2020)
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Authors: Yu Jin Chung, Kyung Chan Park, Sergiy Tokar, Thomas R Eykyn, William Fuller, Davor Pavlovic, Pawel Swietach, Michael J Shattock
Journal: Cardiovascular Research (2020)

Abstract Aims Emipagliflozin (EMPA) is a potent inhibitor of the renal sodium-glucose co-transporter 2 (SGLT2) and an effective treatment for type-2 diabetes. In patients with diabetes and heart failure, EMPA has cardioprotective effects independent of improved glycaemic control, despite SGLT2 not being expressed in the heart. A number of non-canonical mechanisms have been proposed to explain these cardiac effects, most notably an inhibitory action on cardiac Na+/H+ exchanger 1 (NHE1), causing a reduction in intracellular [Na+] ([Na+]i). However, at resting intracellular pH (pHi), NHE1 activity is very low and its pharmacological inhibition is not expected to meaningfully alter steady-state [Na+]i. We re-evaluate this putative EMPA target by measuring cardiac NHE1 activity. Methods and results The effect of EMPA on NHE1 activity was tested in isolated rat ventricular cardiomyocytes from measurements of pHi recovery following an ammonium pre-pulse manoeuvre, using cSNARF1 fluorescence imaging. Whereas 10 µM cariporide produced near-complete inhibition, there was no evidence for NHE1 inhibition with EMPA treatment (1, 3, 10, or 30 µM). Intracellular acidification by acetate-superfusion evoked NHE1 activity and raised [Na+]i, reported by sodium binding benzofuran isophthalate (SBFI) fluorescence, but EMPA did not ablate this rise. EMPA (10 µM) also had no significant effect on the rate of cytoplasmic [Na+]i rise upon superfusion of Na+-depleted cells with Na+-containing buffers. In Langendorff-perfused mouse, rat and guinea pig hearts, EMPA did not affect [Na+]i at baseline nor pHi recovery following acute acidosis, as measured by 23Na triple quantum filtered NMR and 31P NMR, respectively. Conclusions Our findings indicate that cardiac NHE1 activity is not inhibited by EMPA (or other SGLT2i’s) and EMPA has no effect on [Na+]i over a wide range of concentrations, including the therapeutic dose. Thus, the beneficial effects of SGLT2i’s in failing hearts should not be interpreted in terms of actions on myocardial NHE1 or intracellular [Na+].
Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
Authors: Luis E Malpica Castillo, Daniel J Enriquez, Denisse A. Castro, Camila Peña, Henry Idrobo, Lorena Fiad, Maria Prates, Victoria Otero, Mirna Churin, Milagros Altamirano, Gustavo Sandival-Ampuero, Ursula Aviles-Perez, Kelly Meza, Laura Aguirre-Martinez, Cristaldo Nancy, Juan L. Maradei, Luciana Guanchiale, Pablo Soto, Jose Luis Viñuela, Maria Elena Cabrera, Sally Rose Paredes, Eloisa Riva, Marcos Di Stefano, Andrea Noboa, Juan Antonio Choque, Myrna Candelaria, Alana Von Glasenapp, Fabiola Valvert, Marialejandra Torres Viera, Guilherme Fleury Perini, Eduardo Sotomayor, Jorge J. Castillo, Juan Carlos Ramos, Luis Villela Villela, Brady E. Beltrán
Journal: Blood (2020)
Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review
Authors: Muhammad Salman Faisal, Laila Hashim, Yazan Samhouri, Syed Maaz Abdullah, Ahsan Wahab, Moazzam Shahzad, Hamid Ehsan, Zahoor Ahmed, Karun Neupane, Asim Tameez Ud Din, Faiz Anwer, Salman Fazal
Journal: Blood (2020)
A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
Authors: Nina Shah, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, Payal Patel, Liping Huang, Kristen Hege, Sujith Dhanasiri
Journal: Blood (2020)
RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors
Authors: Ali Khateb, Anagha Deshpande, Yongmei Feng, Ikrame Lazar, Joo Sang Lee, Bertrand Fabre, Yan Li, Darren Finlay, Yu Fujita, Tongwu Zhang, Ian Pass, Ido Livneh, Carol Burian, James R. Mason, Ronit Almog, Nurit Horesh, Yishai Ofran, Kevin Brown, Kristiina Vuori, Michael Jackson, Eytan Ruppin, Aniruddha J. Deshpande, Ze'ev A. Ronai
Journal: Blood (2020)
AB0614 METHOTREXATE DOESN’T LOWER THE RISK OF DEVELOPING INTERSTITIAL LUNG DISEASE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES WITH JO-1 ANTIBODIES.
Authors: P. Szczęsny, K. Swierkocka, A. Felis-Giemza, M. Olesińska
Journal: Annals of the Rheumatic Diseases (2020)

Background: In patients with idiopathic inflammatory myopathies (IIM) most commonly found autoantibody against histidyl-tRNA synthetase (anti-Jo-1) is associated with development of interstitial lung disease (ILD), which has been recognized as a serious mortality factor. Objectives: To assess if methotrexate as an initial steroid sparing agent lowers the risk of developing ILD in anti-Jo-1 positive patients diagnosed with IIM. Methods: Medical records of IIM patients treated in a referral clinic in capital city of Poland between 2008 and 2018 were reviewed. Inclusion criteria were: fulfillment of ACR/EULAR 2017 classification criteria for IIM, positivity of anti-Jo-1 antibodies in the EUROLINE test, introduction of corticosteroids equivalent to ≥0,5mg of prednisone. Exclusion criteria: insufficient data on disease course, history of IIM &lt;18 months. Results: 29 patients were included for this analysis. ILD was present at the onset in 52% (n:15) patients. Other 14 patients were treated initially with corticosteroids ≥0,5mg/kg along with methotrexate up to 25mg/week. In all 14 patients methotrexate was well tolerated and led to successful reduction of steroid dose. However, ILD attributed to the primary disease appeared in follow up in 50%(n:7) of these patients (medium 36 months), which resulted in alteration of treatment. In 7 patients ILD didn’t develop. Conclusion: Our study shows that methotrexate in dose up to 25mg/week doesn’t lower the risk of developing ILD in Jo-1 positive IIM patients in the long term suggesting that other medication should be used as a first line treatment for this group. References: [1]Factors affecting survivorship in polymyositis: a life-table study of 124 patients. Medsger TA, Robinson H, Masi AT. Arthritis Rheum 1971;14:249–58 [2](2018). Treatment of adult idiopathic inflammatory myopathies with conventional immunosuppressive drugs. Keyßer, G., Zierz, S., &amp; Kornhuber, M. Z Rheumatol. 2019;78(2):183–189. [3]2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups Lundberg IE, Tjärnlund A, Bottai M, et al. Ann Rheum Dis. 2017;76(12):1955–1964. Disclosure of Interests: None declared
Abstract 433: Regulatory and Elastic Protein Modifications in the Myocardium of Hibernating 13-lined Ground Squirrels
Authors: Maighdlin R Patterson, Jonathan R Groening, Mark A Hiske, Hannah V Carey, Karen L Ball, Charles S Chung
Journal: Circulation Research (2020)

The 13-lined ground squirrel exhibits remarkable cardiac adaptation during hibernation, periods of torpor being interrupted by repeated inter-bout arousal (IBA). During IBA heart rate rises from 2-4 bpm to as great as 300 bpm. This rise in heart rate occurs over just 5 hours and remains elevated for 12-24 hours before returning to the lower heart rate. With such rapid and marked changes in heart rate, and thus filling time, myocardial stiffness and relaxation must be regulated within a short timeframe. The objective of this work was to establish post-translational modifications (PTMs) in two proteins critical to myocardial stiffness and relaxation; titin and cardiac troponin I (TnI). It was specifically hypothesized that phosphorylation during IBA would be similar to that of summer tissue and distinct from tissue isolated during torpor. Left ventricular tissue (summer, n=9; torpor, n=10; IBA, n=7) was solubilized and separated by either 2-12% gradient SDS-Page (titin) or 12.5% SDS-PAGE (TnI). Total titin phosphorylation was measured via Pro-Q Diamond Phosphoprotein/SYPRO Ruby staining. PKA-specific TnI phosphorylation was quantified via western blotting, using a primary antibody specific to Ser 23,24. While there was a tendency toward decreased total titin phosphorylation in IBA, the difference was not significant. In contrast, there were significant group effects in PKA-specific TnI phosphorylation. Phospho-TnI/Total TnI ratios were lower in torpor when compared to summer (0.22±0.12 vs. 0.68±0.,34, p&lt;0.05). While there was no significant difference between summer and IBA (0.62±0.35), the difference between torpor and IBA failed to reach significance. This data supports the hypothesis that rapid changes in heart rates are associated with changes in cardiac troponin-I phosphorylation, a modification that contributes to rapid rates of relaxation. Further dissection of site specific titin phosphorylation will be required to assess the extent to which PTM modify titin associated stiffness. Results from this work may have significant implications in our understanding of altered compliance in human heart failure.
Publisher Correction: Rapid volumetric optoacoustic imaging of neural dynamics across the mouse brain
Authors: Sven Gottschalk, Oleksiy Degtyaruk, Benedict Mc Larney, Johannes Rebling, Magdalena Anastasia Hutter, Xosé Luís Deán-Ben, Shy Shoham, Daniel Razansky
Journal: Nature Biomedical Engineering (2020)
COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
Authors: Delphine Rea, Michael J. Mauro, Jorge E. Cortes, Qian Jiang, Katia B Pagnano, Matilda Ongondi, Chung Hoow Kok, Nicola Evans, Timothy P. Hughes, International CML Foundation
Journal: Blood (2020)
Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies
Authors: Wei Xu, Shenmiao Yang, Constantine S. Tam, John F. Seymour, Keshu Zhou, Stephen Opat, Lugui Qiu, Mingyuan Sun, Tingyu Wang, Judith Trotman, Ling Pan, Sujun Gao, Jianfeng Zhou, Daobin Zhou, Jun Zhu, Yuqin Song, Jianda Hu, Ru Feng, Haiwen Huang, Zhiyue Huang, Huafei Lu, Jianyong Li
Journal: Blood (2020)
Response to: ‘Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia’’ by Huang and Zhang
Authors: Han-You Mo, James Cheng Chung Wei, Xiao-Huan Chen, Hsin-Hua Chen
Journal: Annals of the Rheumatic Diseases (2020)

We thank Huang and Zhang1 for their interest in our article entitled ‘Increased risk of systemic lupus erythematosus (SLE) in patients with autoimmune hemolytic anaemia (AIHA): a nationwide population-based cohort study’.2 In our article, we used nationwide longitudinal population-based data to explore the incidence of systemic lupus erythematosus (SLE) in patients with autoimmune haemolytic anaemia (AIHA) and demonstrated that patients with AIHA are at a very high risk of incidental SLE.2 Huang and Zhang1 have put forward valuable comments and opinions on our article.

First, Huang and Zhang1 proposed that patients with childhood-onset SLE may be more likely to develop AIHA than adulthood-onset patients, and suggested that we describe the incidence of AIHA in patients with SLE of different age groups. Given that it is impossible to provide such information using our original data, we conducted another nationwide cohort study to investigate the risk of AIHA in patients with SLE stratified by age groups (ie, <18 years and ≥18 years). Using the 1997–2013 Taiwanese National Health Insurance Research Database (NHIRD), we identified 6781 newly diagnosed patients with SLE from 2006 to 2013 and randomly selected 130 340 age, sex-matched (1:20) individuals without SLE from one million representative populations. From the cohort, we used propensity score matching (PSM) (1:2) for age, sex, comorbidities and potential confounders (online supplemental table 1). Before PSM, …
Microbial signature in IgE-mediated food allergies
Authors: Michael R. Goldberg, Hadar Mor, Dafna Magid Neriya, Faiga Magzal, Efrat Muller, Michael Y. Appel, Liat Nachshon, Elhanan Borenstein, Snait Tamir, Yoram Louzoun, Ilan Youngster, Arnon Elizur, Omry Koren
Journal: Genome Medicine (2020)

Abstract Background Multiple studies suggest a key role for gut microbiota in IgE-mediated food allergy (FA) development, but to date, none has studied it in the persistent state. Methods To characterize the gut microbiota composition and short-chain fatty acid (SCFAs) profiles associated with major food allergy groups, we recruited 233 patients with FA including milk ( N = 66), sesame ( N = 38), peanut ( N = 71), and tree nuts ( N = 58), and non-allergic controls ( N = 58). DNA was isolated from fecal samples, and 16S rRNA gene sequences were analyzed. SCFAs in stool were analyzed from patients with a single allergy ( N = 84) and controls ( N = 31). Results The gut microbiota composition of allergic patients was significantly different compared to age-matched controls both in α-diversity and β-diversity. Distinct microbial signatures were noted for FA to different foods. Prevotella copri ( P. copri ) was the most overrepresented species in non-allergic controls. SCFAs levels were significantly higher in the non-allergic compared to the FA groups, whereas P. copri significantly correlated with all three SCFAs. We used these microbial differences to distinguish between FA patients and non-allergic healthy controls with an area under the curve of 0.90, and for the classification of FA patients according to their FA types using a supervised learning algorithm. Bacteroides and P. copri were identified as taxa potentially contributing to KEGG acetate-related pathways enriched in non-allergic compared to FA. In addition, overall pathway dissimilarities were found among different FAs. Conclusions Our results demonstrate a link between IgE-mediated FA and the composition and metabolic activity of the gut microbiota.
Plasmablastic Lymphoma: Synergism between<i>Wnt/B-Catenin</i>and the<i>RAS S</i>ignalling Molecules May Identify Potential Targets for Therapy
Authors: Hamza Kamran, Ariz Akhter, Hassan Rizwan, Meer-Taher Shahbani-Rad, Ghaleb Elyamany, Douglas A. Stewart, Adnan Mansoor
Journal: Blood (2020)
Efficacy and Safety Profile of Ixazomib Based Regimens in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis of Clinical Trials
Authors: Ahmad Iftikhar, Muhammad Ashar Ali, Anum Javaid, Muhammad Abu Zar, Atif Sohail, Faryal Razzaq, Rana M Usman, Muhammad Yasir Anwar, Hamza Hassan, Faiz Anwer
Journal: Blood (2020)